TrialAnnals of hematology2025

Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6).

Stephan Fuhrmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.